China NMPA Drug Inspection - Qinghai Baojiantang Traditional Chinese Medicine Co., Ltd. - Huoxiang Zhengqi Water

On March 12, 2020, the Qinghai Provincial Drug Administration released its third announcement regarding drug sampling inspections, specifically targeting medications used for COVID-19 prevention and control. The inspection involved several pharmaceutical manufacturers and distributors, including Qinghai Baojiantang Traditional Chinese Medicine Co., Ltd., Qinghai Jingzhu Tibetan Medicine High-Tech Industry Co., Ltd., Qinghai Jiu Meizang Pharmaceutical Co., Ltd., and Qinghai Xinlvzhou Pharmaceutical Group Co., Ltd., among others. The regulatory review was conducted under the authority of the Drug Administration Law of the People's Republic of China and the Administrative Measures for Drug Quality Sampling and Inspection.

The inspection evaluated 12 batches across 11 drug varieties, including eight medical preparations and three types of traditional Chinese medicine decoction pieces. Testing criteria were based on the 2015 Edition of the Chinese Pharmacopoeia, the Ministry of Health Drug Standards, and various National Drug Standards. The drugs inspected included influenza pills, fever relief granules, and several traditional herbal products like licorice and bitter almond.

Results from the laboratory analysis confirmed that all 12 batches complied with the required safety and quality standards. Because no violations were discovered and all samples met the established regulatory benchmarks, the administration issued no penalties or corrective orders. This announcement serves as a formal verification of compliance for the medications reviewed during this period, ensuring the public that these essential supplies met national quality expectations for quality and efficacy.